Niemann-Pick Disease, Type C Clinical Trial
Official title:
Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Niemann-Pick disease, type C (NPC) is a lethal, autosomal recessive, lysosomal storage disorder characterized by neurodegeneration in early childhood and death in adolescence. NPC results from mutation of either the Niemann-Pick C1 disease (NPC1) (~95% of cases) or NPC2 genes. NPC is characterized by the endolysosomal storage of unesterified cholesterol and lipids in both the central nervous system and peripheral tissues such as the liver. Individuals with NPC demonstrate progressive central nervous system decline including inability to coordinate balance, gait, extremity and eye movements. Acute liver disease in the newborn/infant period is frequently observed, but subsequently resolves. However, chronic, sub-clinical liver disease persists. Intrathecal 2-Hydroxypropyl-β-Cyclodextrin (HP-β-CD, VTS-270), also known as adrabetadex, has proven effective in reducing the signs and prolonging life in animal models and Phase 1/2a data support efficacy in NPC1 patients. Adrabetadex (VTS-270) also has been shown to be effective in treating liver disease in the NPC1 cat. This Phase 1/2a, open-label, multiple ascending dose trial will evaluate whether adrabetadex (VTS-270) administered intravenously is effective in treating acute liver disease in NPC1 infants.
In the first phase of the study, infants will be treated for a total of 6 weeks, treated twice weekly. Infants will be admitted to the Neonatal Intensive Care Unit (NICU) for the first week of treatment. Procedures during the first week of the study will include blood draws for genetic testing, clinical and research blood draws, urine collection, abdominal ultrasound, peripheral inserted central catheter (PICC) placement, hearing screening, and the first two IV adrabetadex (VTS-270) infusions through the PICC line. Weeks 2-6 will occur on an outpatient basis. During week 2-6, the infant will receive 2 doses per week of adrabetadex (VTS-270) with blood draws and urine collection during weeks 2, 4, and 6. PICC line will be removed after final infusion. Subjects who demonstrate significant reduction either in the glycine-conjugated trihydroxycholanic acid biomarker or serum bilirubin (direct bilirubin or direct bilirubin: total bilirubin ratio) will be allowed to crossover into the second phase of the study, an open label phase of six months duration in which IV adrabetadex (VTS-270) will be administered monthly for a total of six doses. Month 1-6 procedures will occur on an outpatient basis. Procedures during the second phase include a monthly intravenous line placement. After each monthly visit, the intravenous line will be removed. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03759639 -
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
|
Phase 2 | |
Withdrawn |
NCT04189601 -
Complement Activation in the Lysosomal Storage Disorders
|
||
Completed |
NCT02435030 -
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C
|
N/A | |
Completed |
NCT02534844 -
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05588167 -
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
|
||
Withdrawn |
NCT03687476 -
Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease
|
Phase 2 | |
Enrolling by invitation |
NCT05368038 -
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
|
||
Completed |
NCT01899950 -
Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
|
N/A | |
Terminated |
NCT00668564 -
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
|
Phase 2 | |
Active, not recruiting |
NCT05163288 -
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
|
Phase 3 | |
Active, not recruiting |
NCT02612129 -
Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C
|
Phase 2/Phase 3 | |
Terminated |
NCT04958642 -
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
|
Phase 2/Phase 3 | |
Terminated |
NCT03879655 -
Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
|
Phase 2/Phase 3 | |
Completed |
NCT00975689 -
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01306604 -
Biomarker for Niemann Pick Type C Disease (BioNPC)
|
||
Recruiting |
NCT00344331 -
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
|
||
Active, not recruiting |
NCT05758922 -
Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
|
Phase 2 | |
Completed |
NCT03910621 -
Safety and Efficacy of Miglustat in Chinese NPC Patients
|
Phase 4 | |
Available |
NCT04316637 -
Early Access Program With Arimoclomol in US Patients With NPC
|